'Golden age' of weight loss jabs coming – some are about to get a lot cheaper
A 'golden age' of weight loss drugs is on the horizon which could finally reverse the rising tide of obesity, scientists say. The leader of the first head-to-head trial comparing the two leading appetite-suppressing jabs revealed at the European Obesity Congress in Malaga, Spain, there are 150 more such drugs in the pipeline.
A host of obesity experts have called on the NHS to urgently ramp up capacity at its weight loss clinics so pills and jabs can be cheaply prescribed to much of the population as they come 'off patent'. Professor Jason Halford, of the European Association for the Study of Obesity, said: 'If the government and NHS are serious about prevention they need to reconsider their position on the speed of the rollout of these drugs, as this evidence comes to light.
"In ten years time the landscape is going to be completely different. There will be lots more obesity drugs available, they should be in more usable forms and they should be a lot more affordable.'
Dr Louis Aronne, director at Weill Cornell Medicine, New York, US, led a trial showing the Mounjaro jab saw users lose 50% more weight than Wegovy, and that newer versions would keep getting better. He said: 'I think we're going to see more medications. The other day I saw a list of 150 medications, many GLP-1s, but also other mechanisms. I call it the golden age of obesity treatment.'
'They will be less expensive, and hopefully the oral small molecules which are cheaper to manufacture and distribute. I think health systems should be ready to roll them out at scale.'
Obesity rates have been rising globally for the last 30 years and more than a billion people are now considered obese. This has contributed to a rising tide of chronic illness, particularly in the West, where we live longer with diseases such as cancer, heart disease, dementia and diabetes placing a huge burden on healthcare systems.
Pharmaceutical companies are pumping tens of billions of pounds into a new generation of appetite-suppressing medicines which could finally help reverse the rise in obesity. Weight loss pills are expected to take over from injections making them more readily available.
Prof Halford added: 'The Holy Grail would be the small molecule, something that works as a hormone would do. But we could take orally like a regular tablet and that's where I think we will be going in probably the next 10 years. In a decade from now we'll have some of the medications off license so they'll be much cheaper. The more treatment we have, the more competition we have, the lower the prices. At the moment the NHS rollout does not take into account the number of medications potentially available in the next 10 years.'
Novo Nordisk manufactures market leading jabs Wegovy and Ozempic, for type 2 diabetes which are both due to come 'off patent' in the coming years so generic versions will be sold for a few pence rather than hundreds of pounds. It also has a pill form of the drugs going through clinical trials.
Another study presented at the conference showed Wegovy halved the risk of dying from stroke or heart attack in people with obesity and cardiovascular disease. The Select trial also found Wegovy protected against heart disease even before people had lost any weight, possibly by reducing inflammation.
Author Professor Donna Ryan, presenting the findings from manufacturer Novo Nordisk, said they "should change public policy everywhere". She added: "I think what our study today does is it further emphasises there is no need to wait. There's always inertia in medicine. We're slow moving. What this analysis says is that this treatment works early - so why wait?'
Currently around half a million Brits are taking the weekly jabs, mainly by paying for private prescriptions, despite over four million being eligible for them on the NHS.
NHS England responded justifying its gradual rollout of jabs such as Mounjaro, which will only see 220,000 people being prescribed it in the next three years due to the cost and resources needed to provide accompanying weight management support from a specialist.
Dr Claire Fuller, NHS England's medical director for primary care, said: 'Weight loss drugs are a powerful part of our arsenal to tackle obesity and support people to lose weight and reduce their risk of other illnesses like diabetes, heart attacks and stroke. From next month, some eligible patients will be able to access the weight loss drug Mounjaro for the first time. The drug has already been approved for use for some adults in specialist weight management services, and 220,000 people will be eligible to benefit over the first three years.
'This phased roll out will ensure those with the greatest clinical need can access the treatment as a priority, at the same time as the NHS develops new and innovative services through which other weight loss treatments can also be delivered in the future. Local NHS organisations will be providing further information on how patients can access services in due course.'
The powerful drugs must be prescribed alongside specialist support to help people transform their diet and activity levels. Without substantial lifestyle changes users will pile the weight back on if they ever come off the jabs. Some people have to stop taking them due to side effects, such as vomiting.
Novo Nordisk patented its blockbuster GLP-1 drug semaglutide in both its branded forms Ozempic and Wegovy. Its 'core' patient expires in 2026 but the pharmaceutical company has 220 'secondary' patients in 28 countries which could extend its market exclusivity to 2033. After then the price of drugs based on its semaglutide molecule will plummet and the availability of generic versions of the drugs will explode.
Other first-generation weight loss jabs such as liraglutide, sold under the brand names Saxenda for obesity and Victoza for diabetes, and dulaglutide, brand name Trulicity, are set to see their patents expire soon paving the way for generic alternatives.
Dr Sonya Babu-Narayan, director at the British Heart Foundation, said: 'A generation ago, effective drugs for obesity would have been a pipe dream. Yet here we are with the potential to make a massive dent in the number of lives cut too short by cardiovascular disease and other conditions such as dementia and cancer. It is imperative that the health service embraces this opportunity and ensures those in need of these lifesaving treatments can access them.'
Big pharma is competing to find new drugs including one drug dubbed the 'Godzilla' of appetite-suppressing injectables which saw trial participants lose up to 24% of their body weight in less than a year. The weekly jab called retatrutide helps the body burn more fat as well as making users feel more full so they eat less. This twin approach has helped it outperform Wegovy, Ozempic and Mounjaro which only suppress appetite.
As well as GLP-1 and GIP hormones, retatrutide targets a third hormone known as glucagon which triggers the body to burn more fat when we move. The trial results showed it helped people with obesity shed 60 pounds on average in just 48 weeks. Women lost even more shedding 28.5% of their body weight compared to 21.2% in the male half of the trial.
But experts insist these drug breakthroughs should not stop political leaders from ignoring the root causes of obesity, namely that society is now set up so we usually have cheap, unhealthy food at our finger tips and it is difficult or expensive to make the healthy choice.
Katharine Jenner, director of the Obesity Health Alliance, said: 'It's no surprise that major pharmaceutical companies are investing heavily in obesity treatment. They recognise the scale of the opportunity. That opportunity exists largely because we've failed to tackle the root causes of obesity.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
31 minutes ago
- The Independent
The new technology for prosthetic legs that could reduce NHS waiting lists by 50%
A new technology could reduce NHS waiting lists for prosthetic legs by half, a study has found. The software personalises prosthetic leg fittings based on data from previous patients. The data-driven fittings for below the knee prosthetics were, on average, as comfortable for patients as those created by highly skilled prosthetists, the NHS trial suggested. Technology developed by Radii Devices and the University of Southampton is hoping to halve the number of clinical visits for the fitting from an average of four to two using the software. The new technology is built to provide a personalised 'socket' using data from other fittings and a 3D scan of the residual limb to immediately generate a basic design. The CEO and founder of Radii Devices, Dr Joshua Steer, said analysing hundreds of previous sockets allowed them to 'identify trends' between different patient characteristics. 'We can then scan a new patient's residual limb and generate a personalised design recommendation based on features that have been successful for similar patients in the past,' he explained. The results of an NHS trial published on Friday in JMIR Rehabilitation and Assistive Technology suggest the new designs are on average as comfortable as those created by a prosthetist. Nineteen sockets were made for 17 participants, as two participants were double amputees, and all bar one of the sockets were above the 'NHS comfort score target', the Radii Devices CEO said. Of those 19 sockets, six of the new designs were reportedly more comfortable than normal prosthetics, while five were less and eight were very similar. Prosthetic sockets are personalised to ensure they are comfortable and functional, as they need to bear a person's body weight without damaging limb tissue or creating discomfort. Traditionally, a prosthetist makes a plaster cast of the leg and reshapes it to produce a socket which achieves the right balance, producing trial versions before settling on a definitive one. Radii Devices says the NHS currently tries to deliver a prosthetic in four clinical visits roughly a month from their first appointment, while the new system can aim for a 'gold standard' of two appointments. Alex Dickinson, Professor of Prosthetics Engineering at the University of Southampton – who helped to develop the new method, acknowledges that it has limits. He said: 'Only a highly skilled prosthetist can identify things like bone spurs and neuromas, and know how to tweak designs to avoid causing pain or damage at these sensitive areas. 'We developed the data-driven socket design approach to save prosthetists' time by giving them a solid base to work from so they can use their expertise where it is most valuable, in making precise adaptations tailored to their patients' specific needs. 'The method effectively helps prosthetists to learn from each other.' Another co-author, Professor Maggie Donovan-Hall, said it was 'surprising and encouraging' that the data-driven sockets performed so well in a test designed as a 'worst case' scenario where they received no additional input from prosthetists. Nearly 100 people have now had a prosthetic leg designed this way, across multiple centres in the UK and the USA. The study has now moved into its final stage where the new software is developed alongside clinicians to see how it can be best incorporated into their practices.
The Independent
31 minutes ago
- The Independent
New software could reduce NHS waiting lists for prosthetic legs, study finds
New software which personalises prosthetic leg fittings based on data from previous patients could help reduce NHS waiting lists, a study has found. The data-driven fittings for below the knee prosthetics were, on average, as comfortable for patients as those created by highly skilled prosthetists, the NHS trial suggested. Technology developed by Radii Devices and the University of Southampton is hoping to halve the number of clinical visits for the fitting from an average of four to two using the software. The new technology is built to provide a personalised 'socket' using data from other fittings and a 3D scan of the residual limb to immediately generate a basic design. The CEO and founder of Radii Devices, Dr Joshua Steer, said analysing hundreds of previous sockets allowed them to 'identify trends' between different patient characteristics. 'We can then scan a new patient's residual limb and generate a personalised design recommendation based on features that have been successful for similar patients in the past,' he explained. The results of an NHS trial published on Friday in JMIR Rehabilitation and Assistive Technology suggest the new designs are on average as comfortable as those created by a prosthetist. Nineteen sockets were made for 17 participants, as two participants were double amputees, and all bar one of the sockets were above the 'NHS comfort score target', the Radii Devices CEO said. Of those 19 sockets, six of the new designs were reportedly more comfortable than normal prosthetics, while five were less and eight were very similar. Prosthetic sockets are personalised to ensure they are comfortable and functional, as they need to bear a person's body weight without damaging limb tissue or creating discomfort. Traditionally, a prosthetist makes a plaster cast of the leg and reshapes it to produce a socket which achieves the right balance, producing trial versions before settling on a definitive one. Radii Devices says the NHS currently tries to deliver a prosthetic in four clinical visits roughly a month from their first appointment, while the new system can aim for a 'gold standard' of two appointments. Alex Dickinson, Professor of Prosthetics Engineering at the University of Southampton – who helped to develop the new method, acknowledges that it has limits. He said: 'Only a highly skilled prosthetist can identify things like bone spurs and neuromas, and know how to tweak designs to avoid causing pain or damage at these sensitive areas. 'We developed the data-driven socket design approach to save prosthetists' time by giving them a solid base to work from so they can use their expertise where it is most valuable, in making precise adaptations tailored to their patients' specific needs. 'The method effectively helps prosthetists to learn from each other.' Another co-author, Professor Maggie Donovan-Hall, said it was 'surprising and encouraging' that the data-driven sockets performed so well in a test designed as a 'worst case' scenario where they received no additional input from prosthetists. Nearly 100 people have now had a prosthetic leg designed this way, across multiple centres in the UK and the USA. The study has now moved into its final stage where the new software is developed alongside clinicians to see how it can be best incorporated into their practices.
Western Telegraph
an hour ago
- Western Telegraph
Manufacturers given 18 months to cut sugar and salt in baby food products
Accompanying new guidelines to clarify labelling on baby food will help parents make informed choices about what they feed their children, the Department of Health and Social Care said. Manufacturers will be challenged to change the recipes for their products to reduce levels of salt and sugar, without the use of sweeteners, which are not permitted for use in commercial baby food. For example, baby desserts and breakfasts such as rice pudding, custard and ready-to-eat fruity porridge should contain less than 10g of total sugar per 100g, while baby meals should have no more than 60mg of salt per 100 calories or 100mg per 100 calories if cheese is included in the recipe. Too often, parents are bombarded with confusing labels, disguising unhealthy foods packed with hidden sugars and salt Public health minister Ashley Dalton The guidelines will also tackle misleading labelling that often conflicts with official feeding advice. For example, some products labelled as snacks for babies from seven months on directly contradict government recommendations that children aged between six and 12 months do not need snacks between meals, only milk. Manufacturers will also be told to stop using misleading marketing claims that make products appear healthier than they are, for example products with labels such as 'contains no nasties' when they may be high in sugar. The move comes as data from the National Diet and Nutrition Survey, published in June, shows that more than two thirds of children aged 18 months to three years are eating too much sugar, while more than a fifth of children aged four to five years are overweight or living with obesity in England. High sugar intake in children's diets is a significant factor contributing to high rates of childhood obesity in the UK, which is among the highest in western Europe. Obesity rates have doubled since the 1990s, including among children. Obesity costs the NHS £11.4 billion a year and is one of the root causes of diabetes, heart disease and cancer. Public health minister Ashley Dalton said: 'Every child deserves a healthy, happy start to life. But babies' development is being harmed by poor diets and unhealthy food, holding them back and piling up pressure on the NHS. It should not even be possible to sell baby food that goes against official feeding guidance, and the public agrees, with three in four people supporting a ban on high-sugar baby foods Katharine Jenner, Obesity Health Alliance 'Too often, parents are bombarded with confusing labels, disguising unhealthy foods packed with hidden sugars and salt. 'Our plan for change will tackle this, giving parents the information they need and providing children with good nutritious food. 'I'm determined to make it far easier for parents to keep their children healthy. 'From working with influencers to get children exercising, to banning junk food ads near schools, our 10-year health plan will help kids today be part of the healthiest generation of children ever.' Katharine Jenner, director of the Obesity Health Alliance, said: 'For too long, commercial baby foods have been promoting high-sugar products disguised as 'healthy options', using misleading packaging. 'These new guidelines put the industry on notice: this practice must end. 'Making it easier for parents to buy healthier products is a baby step in the right direction – but what's really needed is a giant leap. 'It should not even be possible to sell baby food that goes against official feeding guidance, and the public agrees, with three in four people supporting a ban on high-sugar baby foods. Our research has consistently shown excessive levels of sugars in commercial baby foods Dr Kawther Hashem, Action on Sugar 'If the industry fails to act quickly, the Government must step in with mandatory rules to set children up for a lifetime of good health.' Dr Kawther Hashem, head of research and impact at Action on Sugar, said: 'Our research has consistently shown excessive levels of sugars in commercial baby foods. 'These long-overdue voluntary guidelines are a step in the right direction, but they must not be the final word. 'Consuming too much sugar on a regular basis means children are taking in excess calories that, if not used for energy, are stored as fat. 'This increases the risk of weight gain and, if it starts early, that excess weight is often carried into adolescence and adulthood, raising the risk of overweight, obesity and agonising tooth decay. 'If we're serious about protecting our youngest children, these guidelines must be made mandatory. 'We urge the Government to closely monitor progress and act swiftly if companies fail to change.' The industry has been warned to clean up their act with voluntary guidelines, but to truly protect children, mandatory standards are needed Dr Hannah Brisden, Food Foundation Professor Simon Kenny, NHS England's national clinical director for children and young people, said: 'I can't overstate just how important good nutrition is during these formative months for babies' health in the long term, and you can't beat fresh foods. 'Reducing the salt and sugar levels in shop-bought baby food is a really important step, and these new guidelines alongside clearer labelling will help empower busy parents to make nutritious choices that give their children the best possible start in life.' Dr Hannah Brisden, head of policy and advocacy at the Food Foundation, said: 'Giving every child the best start in life begins with good nutrition. 'Today's announcement on commercial baby foods highlights the need to protect families from aggressive marketing and end misleading claims on sugary products. 'Our research found up to 43 claims on a single baby snack, despite many being high in sugar. 'The industry has been warned to clean up their act with voluntary guidelines, but to truly protect children, mandatory standards are needed. 'We urge the Government to monitor progress closely and be ready to step in if companies don't act.'
